Our goal is to deliver the power of the dynamic genome to every life scientist’s bench
MAGNA’s low sample input requirements, multiple analytical modes, and high quality data, enables it to address critical unmet needs in applications such as…
Epigenetic biomarkers are core to an increasing number of diagnostic tests, especially in the area of liquid biopsy for early cancer detection. Most tests rely on only one epigenetic mark, the DNA base modification 5-methylcytosine (m5C). MAGNA™ not only greatly simplifies m5C analysis, but can also detect many of the other 170+ epigenetic marks on DNA and RNA, with unparalleled sensitivity and specificity. When combined with the ability to identify DNA fragments as well as determine length, the technology has the power to simplify existing tests and dramatically expand the range of epigenetic biomarkers.
MAGNA™ can be used to study the interactions of small molecule therapeutics with their targets in real-time at the single-molecule level, revealing the dynamics of the binding events in high-definition. MAGNA™ will provide powerful new insights into both target validation and hit-to-lead areas of drug development.
Whereas the static, four-base code of the static genome is now well understood, precious little is yet understood about dynamic genomics – epigenetics, epitranscriptomics and interactomics – because of the lack of effective tools to study them. MAGNA™ opens the door to researchers in these fields, which will in turn help unlock the secrets of biological function.